



BRIAN SANDOVAL
Governor

STATE OF NEVADA
DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY

1100 E. William Street, Suite 101
Carson City, Nevada 89701
www.dhcfp.nv.gov

MICHAEL J. WILLDEN
Director

CHARLES DUARTE
Administrator

Nevada Medicaid
Drug Use Review (DUR) Board

The Division of Health Care Financing and Policy (DHCFP) Drug Use Review (DUR) Board will conduct a public meeting on July 26th, 2012 beginning at 1:00 pm at the following location:

**Nevada State Health Division
3811 W. Charleston Blvd, Suite 112
Las Vegas, NV 89102**

Some members will be attending the conference via video conference at: Nevada State Health Division, 4150 Technology Way, Suite 300, Carson City, Nevada 89506 (seating is limited).

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Rita Mackie at: 775-684-3681 or email: rmackie@dhcfp.nv.gov in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Meeting material may be found at: <http://www.medicaid.nv.gov/providers/rx/rxmeetings.aspx>

Items may be taken out of order.
Items may be combined for consideration by the public body.
Items may be pulled or removed from the agenda at any time.

Public comment is limited to 5 minutes per individual, organization, or agency, but may be extended at the discretion of the Chairperson.

1) Call to Order and Roll Call

2) Public Comment

No action may be taken on a matter raised under this item of the agenda until the matter itself has been specifically included on the agenda as an item upon which action can be taken.

3) Administrative

a) For Possible Action: Review and Approve January 26, 2012 Meeting Minutes

- b) Status Update by DHCFP
 - i) Public Comment
 - ii) Program Updates

4) Clinical Presentations

- c) Presentation of Acetaminophen containing products
 - i) Public Comment
 - ii) Discussion by Board on Review of Utilization Data
 - iii) **For Possible Action:** Add quantity limits to acetaminophen containing products so not to exceed Board Recommended amounts.
- d) Presentation of Daliresp therapy for COPD
 - i) Public Comment
 - ii) Discussion by Board on Review of Utilization Data and Use in COPD Treatment
 - iii) **For Possible Action:** Adoption of Clinical Prior Authorization Criteria.
- e) Presentation of Xarelto use and clinical information
 - i) Public Comment
 - ii) Discussion by Board on Review of Utilization Data
 - iii) **For Possible Action:** Adoption of Clinical Prior Authorization Criteria
- f) Presentation of Bydureon and Victoza use and clinical information
 - i) Public Comment
 - ii) Discussion by Board on Review of Utilization Data
 - iii) **For Possible Action:** Adoption of Clinical Prior Authorization Criteria.
- g) Presentation of Kalydeco for Cystic Fibrosis
 - i) Public Comment
 - ii) Discussion by Board on Review of Utilization Data
 - iii) **For Possible Action:** Adoption of Clinical Prior Authorization Criteria.
- h) Presentation of Natroba for Lice and Scabies
 - i) Public Comment
 - ii) Discussion by Board on Review of Utilization Data
 - iii) **For Possible Action:** Adoption of Step therapy requirements
- i) Presentation of Brilinta use and clinical information
 - i) Public Comment
 - ii) Discussion by Board on Review of Utilization Data
 - iii) **For Possible Action:** Adoption of Clinical Prior Authorization Criteria
- j) Presentation of Lyrica use and clinical information
 - i) Public Comment
 - ii) Discussion by Board on Review of Utilization Data
 - iii) **For Possible Action:** Update of Clinical Prior Authorization Criteria

- k) Presentation of Diastat use and clinical information
 - i) Public Comment
 - ii) Discussion by Board on Review of Utilization Data
 - iii) **For Possible Action:** Adoption of Step therapy requirements
- l) Presentation of Abilify use and clinical information
 - i) Public Comment
 - ii) Discussion by Board on Review of Utilization Data
 - iii) **For Possible Action:** Update of Clinical Prior Authorization Criteria
- m) Presentation of Xopenex use and clinical information
 - i) Public Comment
 - ii) Discussion by Board on Review of Utilization Data
 - iii) **For Possible Action:** Update of Clinical Prior Authorization Criteria

5) DUR Board Requested Reports

- a) Presentation of Makena and 17-alpha hydroxyl progesterone utilization data
 - i) Discussion by Board on Review of Utilization Data
- b) Presentation of Carisoprodol and Carisoprodol Compound utilization data and information from Nevada Controlled Substance Task Force
 - i) Public Comment
 - ii) Discussion by Board on Review of Utilization Data
 - iii) **For Possible Action by the Board**
- c) Muscle Relaxants, recipients using more than one agent
 - i) Public Comment
 - ii) Discussion by Board on Review of Utilization Data
 - iii) **For Possible Action by the Board**
- d) Immunization Data
 - i) Discussion by Board on Review of Utilization Data
- e) Top 10 Black Box warning medications
 - i) Public Comment
 - ii) Discussion by Board on Review of Utilization Data
 - iii) **For Possible Action by the Board**
- f) Report on number of recipients receiving 800mg of Celebrex per day
 - i) Public Comment
 - ii) Discussion by Board on Review of Utilization Data
 - iii) **For Possible Action by the Board**

- g) Report on Promethazine with Codeine syrup use
 - i) Public comment
 - ii) Discussion by Board on Review of Utilization Data
 - iii) **For Possible Action by the Board**
- h) Presentation of Hyperparathyroid therapies
 - i) Discussion by Board on Review of Utilization Data
- i) Presentation of Iron Replacement Therapies
 - i) Discussion by Board on Review of Utilization Data
- j) Presentation of analgesics and anticonvulsant classes/cost, drug mix analysis
 - i) Public Comment
 - ii) Discussion by Board on Review of Utilization Data
 - iii) **For Possible Action by the Board**
- k) Presentation of List of Outstanding DUR Board Report Requests
 - i) Discussion by Board on Review of Utilization Data

6) Standard DUR Reports

- a) Review of Prescribing/Program Trends
 - i) Public Comment
 - ii) Program Trends
 - iii) Top 10 Therapeutic Classes for Q4 2011, Q1 2012 and Q2 2012 (by Payment and by Claims)
 - iv) Top 50 Drugs of Q4 2011, Q1 2012 and Q2 2012 (by Payment and by Claims)
- b) Concurrent Drug Utilization Review (ProDUR)
 - i) Public Comment
 - ii) Review of Q4 2011, Q1 2012 and Q2 2012
 - iii) Review of Top Encounters by Problem Type
- c) Retrospective Drug Utilization Review (RetroDUR)
 - i) Public Comment
 - ii) Review of Responses
 - iii) Status of Previous Quarter
 - iv) Status of Current Quarter
 - v) **For Possible Action:** Board Discussion and Approval of Future Criteria Selection

7) Closing Discussion

- a) Public Comment

- b) Date and Location of next meeting
 - i) Discussion of new time of next meeting.
- c) Adjournment

This notice and agenda has been posted on or before 9:00 am on the third working day before the meeting at the following locations:

Notice of this meeting will be available on or after the posting date of this Agenda at the DHCFP Web site (www.medicaid.nv.gov).

Posting of the Agenda will be at the Nevada Medicaid Central offices in Carson City and Las Vegas; Nevada State Library; Carson City Library; Churchill Country Library; Las Vegas Library; Douglas County Library; Elko County Library, Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the action items will be mailed to you or they may be reviewed Monday through Friday from 9:00 until 5:00 pm or at the meeting. Please call at least one day ahead for an appointment for document review. Written comments on the proposed changes may be sent to DHCFP, 1100 E. William Street, Suite 102, Carson City, NV 89701.

All persons that have requested in writing to receive the Open Meeting Agenda have been duly notified by mail or e-mail.

Anyone presenting documents for consideration during the public comment portion of the meeting must provide sufficient copies for each member of the committee and the official record. Copies are to be distributed at the time of the meeting and should be provided at meeting locations; DHCFP or its contractor will not distribute public comment information or materials prior to the public meeting.